Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 19/20 | 0.95 |
| ▸ | CYSLTR1 | Q9Y271 | 18/20 | 0.95 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102813 | 1.00 | CYSLTR2 (0.95) | CYSLTR2CYSLTR1S1PR1S1PR3 | |
| SCHEMBL3094496 | 0.98 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL3105249 | 0.98 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL3094491 | 0.98 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL3098766 | 0.97 | CYSLTR2 (0.98) | CYSLTR2CYSLTR1 | |
| SCHEMBL3098773 | 0.97 | CYSLTR2 (0.98) | CYSLTR2CYSLTR1 | |
| SCHEMBL3094357 | 0.94 | CYSLTR2 (0.84) | CYSLTR2CYSLTR1S1PR1S1PR3 | |
| SCHEMBL3094441 | 0.94 | CYSLTR2 (0.84) | CYSLTR2CYSLTR1S1PR1S1PR3 | |
| SCHEMBL3094435 | 0.94 | CYSLTR2 (0.84) | CYSLTR2CYSLTR1S1PR1S1PR3 | |
| SCHEMBL3094358 | 0.94 | CYSLTR2 (0.84) | CYSLTR2CYSLTR1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1661892-B1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8318952-B2 | Substituted indole derivatives for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2481732-A1 | Condensed ring compound and use thereof | Ono Pharmaceutical Co., Ltd. (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | TAKEUCHI JUN | 2010-09-16 | — | — | US | disclosed |
| US-7763610-B2 | Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20060194797-A1 | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR2 1/4885CYSLTR1 2/4885S1PR1 2840/4885 |
| US-20060194797-A1 | Condensed ring compound and use thereof | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR2 1/4885CYSLTR1 2/4885S1PR1 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.